Cathepsin B degrades amyloid-β in mice expressing wild-type human amyloid precursor protein

Journal of Biological Chemistry

Volumn 287, Issue 47, 2012, Pages 39834-39841

  Wang, Chao ^a,b   Sun, Binggui ^a,b   Zhou, Yungui ^a   Grubb, Anders ^c   Gan, Li ^a,b  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOLOGY;

AMYLOID BETAS; AMYLOID PRECURSOR PROTEINS; CATHEPSIN B; WILD TYPES;

GLYCOPROTEINS;

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CATHEPSIN B; CYSTATIN C; NEURON SPECIFIC ENOLASE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); APP PROTEIN, HUMAN; CTSB PROTEIN, HUMAN; CTSB PROTEIN, MOUSE; CYSTATIN; NERVE PROTEIN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAR WESTERN BLOTTING; GENE DELETION; GENE OVEREXPRESSION; GENOTYPE; IN VIVO STUDY; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEINASE INHIBITION; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE; ANIMAL; GENE EXPRESSION; GENETIC DISORDER; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; MUTATION; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CATHEPSIN B; CYSTATINS; GENE DELETION; GENE EXPRESSION; GENETIC DISEASES, INBORN; HUMANS; MICE; MICE, KNOCKOUT; MUTATION; NERVE TISSUE PROTEINS; NEURONS; PEPTIDE FRAGMENTS; PROTEOLYSIS;

EID: 84873964654     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.371641     Document Type: Article

References (33)

1. Tanzi, R. E., Moir, R. D., and Wagner, S. L. (2004) Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron 43, 605-608
2. Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., and Love, S. (2011) Aβ- degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 70, 944-959
3. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H. J., and Saido, T. C. (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292, 1550-1552
4. Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., Hsu, C. Y., Holtzman, D. M., and Lee, J. M. (2006) Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281, 24566-24574
5. Eckman, E. A., Reed, D. K., and Eckman, C. B. (2001) Degradation of the Alzheimer's amyloid-β peptide by endothelin-converting enzyme. J. Biol. Chem. 276, 24540-24548
6. Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., and Selkoe, D. J. (1998) Insulindegrading enzyme regulates extracellular levels of amyloid-β protein by degradation. J. Biol. Chem. 273, 32730-32738
7. Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E. D., Sun, B., Chen, J., Wang, X., Yu, G., Esposito, L., Mucke, L., and Gan, L. (2006) Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51, 703-714
8. Sun, B., Zhou, Y., Halabisky, B., Lo, I., Cho, S. H., Mueller-Steiner, S., Devidze, N., Wang, X., Grubb, A., and Gan, L. (2008) Cystatin C-cathepsin B axis regulates amyloid-β levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60, 247-257
9. Hook, V. Y., Kindy, M., Reinheckel, T., Peters, C., and Hook, G. (2009) Genetic cathepsin B deficiency reduces β-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem. Biophys. Res. Commun. 386, 284-288
10. Banati, R. B., Rothe, G., Valet, G., and Kreutzberg, G. W. (1993) Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurement and histochemical localization of cathepsins B and L. Glia 7, 183-191
11. Cataldo, A. M., Barnett, J. L., Pieroni, C., and Nixon, R. A. (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J. Neurosci. 17, 6142-6151
12. Deussing, J., Roth, W., Saftig, P., Peters, C., Ploegh, H. L., and Villadangos, J. A. (1998) Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc. Natl. Acad. Sci. U.S.A. 95, 4516-4521
13. Huh, C. G., Hakansson, K., Nathanson, C. M., Thorgeirsson, U. P., Jonsson, N., Grubb, A., Abrahamson, M., and Karlsson, S. (1999) Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol. Pathol. 52, 332-340
14. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. (2000) High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058
15. Raber, J., Wong, D., Buttini, M., Orth, M., Bellosta, S., Pitas, R. E., Mahley, R. W., and Mucke, L. (1998) Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl. Acad. Sci. U.S.A. 95, 10914-10919
16. Johnson-Wood, K., Lee, M., Motter, R., Hu, K., Gordon, G., Barbour, R., Khan, K., Gordon, M., Tan, H., Games, D., Lieberburg, I., Schenk, D., Seubert, P., and McConlogue, L. (1997) Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 94, 1550-1555
17. Turk, B., Bieth, J. G., Björk, I., Dolenc, I., Turk, D., Cimerman, N., Kos, J., Colic, A., Stoka, V., and Turk, V. (1995) Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. Biol. Chem. Hoppe-Seyler 376, 225-230
18. Cimerman, N., Prebanda, M. T., Turk, B., Popovic, T., Dolenc, I., and Turk, V. (1999) Interaction of cystatin C variants with papain and human cathepsins B, H, and L. J. Enzyme Inhib. 14, 167-174
19. Golde, T. E., Eckman, C. B., and Younkin, S. G. (2000) Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta 1502, 172-187
20. Butler, D., Hwang, J., Estick, C., Nishiyama, A., Kumar, S. S., Baveghems, C., Young-Oxendine, H. B., Wisniewski, M. L., Charalambides, A., and Bahr, B. A. (2011) Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PLoS ONE 6, e20501
21. Turk, B., Turk, D., and Salvesen, G. S. (2002) Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. 8, 1623-1637
22. McConlogue, L., Buttini, M., Anderson, J. P., Brigham, E. F., Chen, K. S., Freedman, S. B., Games, D., Johnson-Wood, K., Lee, M., Zeller, M., Liu, W., Motter, R., and Sinha, S. (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 282, 26326-26334
23. Nixon, R. A., and Yang, D. S. (2011) Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol. Dis. 43, 38-45
24. Lee, J. H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., Uchiyama, Y., Westaway, D., Cuervo, A. M., and Nixon, R. A. (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer- related PS1 mutations. Cell 141, 1146-1158
25. Yang, D. S., Stavrides, P., Mohan, P. S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S. D., Wesson, D., Bandyopadhyay, U., Jiang, Y., Pawlik, M., Peterhoff, C. M., Yang, A. J., Wilson, D. A., St George-Hyslop, P., Westaway, D., Mathews, P. M., Levy, E., Cuervo, A. M., and Nixon, R. A. (2011) Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 134, 258-277
26. Gan, L., Ye, S., Chu, A., Anton, K., Yi, S., Vincent, V. A., von Schack, D., Chin, D., Murray, J., Lohr, S., Patthy, L., Gonzalez-Zulueta, M., Nikolich, K., and Urfer, R. (2004) Identification of cathepsin B as a mediator of neuronal death induced by Aβ-activated microglial cells using a functional genomics approach. J. Biol. Chem. 279, 5565-5572
27. Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., and Golenbock, D. T. (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 9, 857-865
28. Yang, C. N., Shiao, Y. J., Shie, F. S., Guo, B. S., Chen, P. H., Cho, C. Y., Chen, Y. J., Huang, F. L., and Tsay, H. J. (2011) Mechanism mediating oligomeric Aβ clearance by naïve primary microglia. Neurobiol. Dis. 42, 221-230
29. Tagawa, K., Maruyama, K., and Ishiura, S. (1992) Amyloid-β/A4 precursor protein (APP) processing in lysosomes. Ann. N.Y. Acad. Sci. 674, 129-137
30. Tsujinaka, T., Ebisui, C., Fujita, J., Morimoto, T., Ogawa, A., Ishidoh, K., Kominami, E., Yano, M., Shiozaki, H., and Monden, M. (1995) Autocatalytic inactivation of lysosomal cathepsins is associated with inhibition of protein breakdown by insulin-like growth factor-1 (IGF-1) in myotubes. Biochem. Biophys. Res. Commun. 208, 353-359
31. Authier, F., Métioui, M., Bell, A. W., and Mort, J. S. (1999) Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J. Biol. Chem. 274, 33723-33731
32. Deng, A., Irizarry, M. C., Nitsch, R. M., Growdon, J. H., and Rebeck, G. W. (2001) Elevation of cystatin C in susceptible neurons in Alzheimer's disease. Am. J. Pathol. 159, 1061-1068
33. Viswanathan, K., Hoover, D. J., Hwang, J., Wisniewski, M. L., Ikonne, U. S., Bahr, B. A., and Wright, D. L. (2012) Nonpeptidic lysosomal modulators derived from A-Phe-Ala-diazomethylketone for treating protein accumulation diseases. ACS Med. Chem. Lett., in press